4DMedical Limited (ASX:4DX) is an Australian-headquartered medical technology company developing breakthrough lung imaging and cardiopulmonary diagnostic technology. Headquartered in Melbourne and listed on the ASX in 2020, 4DMedical's flagship XV Technology applies advanced computational and imaging algorithms to standard X-ray and CT scan data to generate dynamic, four-dimensional images of lung function. The technology aims to provide more accurate, less invasive, and more cost-effective diagnostic capabilities than traditional methods including pulmonary function tests and ventilation/perfusion (V/Q) scans. For Australian investors, 4DX is a small-cap medical technology stock with high growth potential and pre-profit operating characteristics.

This article provides a general information overview of 4DMedical's Business, the operating context of the global lung imaging and cardiopulmonary diagnostics sector, recent financial performance, strategic priorities, competitive position and key risks. It draws on the FY25 result released in late 2025 and selected sector context. It contains no share-price target, no recommendation, and is intended only as general information for investors conducting their own research.

Company Overview

4DMedical's core technology platform is XV Technology, which applies proprietary computational algorithms to standard imaging data (chest X-rays and CT scans) to generate dynamic visualisations of lung ventilation function. The technology allows clinicians to assess regional lung performance in detail, identifying conditions including chronic obstructive pulmonary disease (COPD), asthma, constrictive bronchiolitis, post-COVID lung damage, occupational lung disease and other respiratory conditions.

The company's commercial portfolio includes XV LVAS (Lung Ventilation Analysis Software) and the recently FDA-cleared CT:VQ platform — the latter representing a non-invasive alternative to traditional nuclear medicine V/Q scans for assessing pulmonary embolism and other ventilation/perfusion abnormalities. The US Centers for Medicare & Medicaid Services (CMS) confirmed reimbursement for the CT:VQ technology at approximately US$650.50 per scan, on top of the healthcare provider's standard chest CT payments.

4DMedical operates a software-as-a-service (SaaS) Business model, with healthcare providers (hospitals, imaging centres, clinics) sending imaging data to 4DMedical's cloud-based platform for processing. The platform returns analysis results, with Revenue earned on a per-scan basis or under selected subscription arrangements. The company also operates clinical research collaborations with major US academic medical centres including Vanderbilt University Medical Center, the University of Miami and Alfred Health.

In late 2024, 4DMedical signed a US reseller agreement with Philips, providing access to one of the largest healthcare technology distribution networks globally. The Philips relationship has been a strategic enabler of broader US commercial expansion.

Sector and Industry Context

The global lung imaging and cardiopulmonary diagnostics sector is supported by long-term structural drivers including an ageing population (with rising prevalence of respiratory conditions), continued growth in chronic disease management programs, ongoing improvements in imaging technology, and the broader digital transformation of healthcare. Respiratory conditions including COPD, asthma, post-COVID lung damage and occupational lung disease affect substantial populations globally.

Traditional pulmonary function testing (PFT) measures lung capacity and flow but provides limited regional or dynamic information. Nuclear medicine V/Q scans (used to assess pulmonary embolism and ventilation/perfusion abnormalities) provide regional information but require radioactive tracers, specialised equipment and longer scan times. CT angiography, used for pulmonary embolism diagnosis, exposes patients to higher radiation doses and contrast risks.

4DMedical's XV Technology and CT:VQ platforms are positioned as alternatives to these traditional approaches, leveraging existing chest imaging infrastructure (X-ray and CT) without requiring additional hardware or radioactive tracers. The strategic positioning aligns with broader healthcare trends toward less invasive diagnostics, integrated electronic patient records, and value-based care delivery.

Sector challenges include the slow pace of clinical adoption (with new technology requiring extensive evidence generation, regulatory clearance, reimbursement establishment and clinician education), competitive activity from established imaging and AI-driven diagnostic technology providers, and the inherent Capital intensity of building a global commercial healthcare technology Business.

Business Model

4DMedical operates a SaaS Business model, with Revenue earned principally on a per-scan basis from healthcare provider customers using XV LVAS and CT:VQ platforms. The cloud-based platform supports scalable Revenue with relatively low marginal cost per scan, providing the basis for substantial Leverage/">Operating Leverage as scan volumes grow.

Revenue sources include direct sales to US imaging centres and hospitals (supported by the CMS reimbursement framework for CT:VQ), commercial relationships with the US Department of Veterans Affairs (supporting deployment-related lung disease screening for US military veterans), the Philips US reseller agreement (providing access to a broad customer base), and selected international commercial relationships.

Leverage/">Operating Leverage benefits 4DMedical as scan volumes grow. Once R&D, regulatory approval, reimbursement establishment and commercial infrastructure are in place, additional scan volumes contribute strongly to gross margins. The company has reported strong scan growth trajectory, with nearly 200,000 scans completed across 388 sites globally in FY25, including 74,000 scans in the June 2025 quarter alone.

Capital intensity has been moderate but rising as the company scales US commercial infrastructure, continues clinical evidence generation, and supports ongoing platform development. The company has historically been pre-profit, with continued Investment funded through periodic Capital raisings.

Recent Financial Performance

For the year ended 30 June 2025, 4DMedical reported operating Revenue of approximately A$5.9 million, up 56% on FY24, with SaaS Revenue of A$5.7 million. Gross Profit was A$5.4 million, reflecting strong gross margins on the SaaS-based Revenue model. Total income (including operating Revenue, grants and other income) reached A$16.5 million, supported by ongoing clinical research collaborations and selected government grants.

Operating losses continued, with reported EBITDA of approximately negative A$24.9 million and net loss of A$30.1 million (down 17% on FY24). The reduced loss reflected improving Leverage/">Operating Leverage as scan volumes grew, partially offset by continued Investment in US commercial expansion, regulatory affairs, and ongoing platform development.

Operationally, FY25 was a transformational period for 4DMedical. Global utilisation increased materially, with nearly 200,000 scans completed across 388 sites — a substantial increase on prior periods. The standout achievement was securing FDA clearance for the breakthrough CT:VQ platform, with CMS confirming reimbursement at approximately US$650.50 per scan on top of standard chest CT payments. This combination of regulatory clearance and reimbursement establishes the commercial foundation for substantial scan Volume growth in the United States.

A study conducted with Vanderbilt University Medical Center, the University of Miami and Alfred Health demonstrated that XV Technology could replicate surgical biopsy results in detecting deployment-related constrictive bronchiolitis among US military veterans, with up to 98% agreement. This evidence supports both Department of Veterans Affairs deployment and broader clinical adoption.

Strategy and Growth Drivers

4DMedical's strategy is built on five core themes: scaling commercial deployment of CT:VQ in the United States following FDA clearance and CMS reimbursement, leveraging the Philips US reseller relationship for broader market access, deepening Department of Veterans Affairs and Department of Defense engagement around military veteran lung disease screening, continuing clinical evidence generation across new indications, and selective international commercial expansion.

Within the United States, the focus is on accelerating CT:VQ deployment across hospitals and imaging centres, leveraging the established CMS reimbursement framework. The Philips reseller relationship provides access to a substantial existing customer base of imaging equipment and software users, supporting commercial scale.

Department of Veterans Affairs engagement has been a particular strategic priority, supported by the clinical evidence around deployment-related constrictive bronchiolitis and the broader lung disease burden among military veterans. Continued deployment across the VA system, alongside potential Department of Defense applications, supports a substantial addressable population.

Clinical evidence generation remains essential. Ongoing collaborations with major academic medical centres support the development of evidence supporting new indications, expanded clinical applications, and broader specialist endorsement. Regulatory clearance for additional indications, alongside reimbursement establishment in international markets, supports longer-term growth.

Capital allocation priorities include funding ongoing US commercial expansion, R&D Investment, clinical evidence generation, and maintaining a strong Balance Sheet. The company has historically funded operations through periodic Capital raisings, and continued Capital management discipline remains important during the pre-profit phase.

Competitive Position

4DMedical's competitive position is built on the proprietary XV Technology platform, FDA clearance and CMS reimbursement for CT:VQ, growing commercial customer base, the Philips US reseller relationship, and the substantial clinical evidence base developed through major academic collaborations.

Competitors include established imaging technology providers (such as GE HealthCare, Siemens Healthineers, Philips and Canon Medical, although Philips is also a partner), AI-driven medical imaging companies (such as Aidoc, Annalise.ai, RadAI and Lunit), specialist pulmonary diagnostic technology providers, and traditional nuclear medicine V/Q and pulmonary function testing equipment manufacturers.

Areas of relative strength include the differentiated XV Technology approach, the FDA-cleared and CMS-reimbursed CT:VQ platform, the strong clinical evidence base, the Philips reseller relationship, and growing engagement with the Department of Veterans Affairs and academic medical centres. Areas of relative weakness include the small absolute scale of operations, the inherent slow pace of clinical adoption, the pre-profit financial profile, and the substantial Capital required to support full US commercial scale-up.

Risks and Challenges

Commercial adoption risk is the most material variable. Despite FDA clearance and CMS reimbursement for CT:VQ, scan Volume growth depends on continued education of clinicians, integration with hospital and imaging centre workflows, supportive specialty society endorsements, and broader recognition of the technology's clinical value. Adoption rates may be slower than expected.

Capital and balance-sheet risk is structural for a pre-profit medical technology company. 4DMedical has historically funded operations through periodic Capital raisings, with continued Investment in US commercial expansion, R&D and clinical evidence generation requiring ongoing Capital availability. Equity dilution risk is therefore relevant.

Regulatory and reimbursement risk applies particularly to international markets and new indications. The CMS reimbursement framework for CT:VQ provides US commercial visibility, but reimbursement establishment in other major markets (such as the United Kingdom, European Union, Japan and Australia) requires further work. New indication approvals also require ongoing clinical evidence generation and regulatory engagement.

Competition risk is significant. Established imaging technology providers and AI-driven medical imaging companies are investing substantially in adjacent and competing capabilities. Maintaining technology Leadership and clinical evidence advantages is essential.

Other risks include cyber-security risks (particularly relevant given the cloud-based platform handling patient imaging data), execution risk on US commercial scale-up, currency translation risk (with substantial US dollar Revenue), and broader macroeconomic exposure to healthcare spending and Capital availability.

Outlook

Over the next 12 to 24 months, investors are likely to monitor several variables. CT:VQ commercial scan Volume growth in the United States, supported by FDA clearance, CMS reimbursement and the Philips reseller relationship, will be the primary indicator of underlying Business momentum. XV LVAS scan volumes, particularly through Department of Veterans Affairs deployment, will be a continued contributor to growth.

Strategic milestones include continued evidence generation across new indications, ongoing regulatory clearance for adjacent applications, additional commercial customer wins, and any updates on international market entry. Margin trajectory, supported by Leverage/">Operating Leverage from scan Volume growth, will be relevant to the path toward profitability.

Capital management decisions, including the timing of any further Capital raisings, will reflect Cash Flow generation and ongoing Investment requirements. Sector-level variables include the trajectory of US healthcare spending, broader Investment in lung disease diagnostics following the COVID-era heightened awareness, regulatory developments affecting AI-based medical imaging, and competitive activity from imaging technology providers and specialist diagnostic companies.

Conclusion

4DMedical is a small-cap, high-growth medical technology Business with proprietary lung imaging and cardiopulmonary diagnostic technology in commercial deployment in the United States. It offers Australian investors Leverage to the long-term respiratory diagnostics thematic, supported by FDA clearance, CMS reimbursement, the Philips reseller relationship, and strong clinical evidence development.

Investors evaluating 4DX typically weigh the company's differentiated technology, regulatory clearance, growing scan volumes and strategic partnerships against the inherent risks of pre-profit medical technology Investment, Capital and balance-sheet considerations, commercial adoption pace, and competitive intensity. As with all general information of this nature, individual decisions should be made with reference to personal circumstances and, where appropriate, professional advice.

Additional Considerations

4DMedical's Investment narrative reflects a distinctive combination of substantial intellectual property, clinical evidence and regulatory progress alongside the inherent uncertainties of pre-profit medical technology Investment. The transition through FY25 — including FDA clearance for CT:VQ, CMS reimbursement establishment, the Philips reseller relationship and scan Volume acceleration — represents meaningful commercial maturation. However, continued US commercial scale-up, broader international deployment, and the eventual transition to profitability all remain strategic priorities.

The healthcare sector context is also relevant. Heightened awareness of lung disease following the COVID-19 Pandemic, ongoing burden of respiratory conditions globally, and the broader trend toward less invasive and more accessible diagnostics support the addressable market thesis. The combination of XV Technology's regional and dynamic lung function imaging with established CT and X-ray infrastructure represents a distinctive value proposition.

From an investor positioning perspective, 4DX is one of the higher-profile small-cap medical technology stocks listed on the ASX. index inclusion is limited given the company's Market Capitalisation, and trading volumes can be volatile. The combination of intellectual property strength, regulatory progress and commercial momentum is balanced against the typical risks of pre-profit medical technology Investment, including Capital availability, commercial adoption pace and ongoing development complexity.